

# Neuroendokrine kolorektale Karzinome

## Auswertung der Daten des Klinischen Krebsregisters Chemnitz von 2009 bis 2021

D. Quietzsch, M. A. Neubert, J.-O. Habeck, B. Schubotz

### Literatur

- [1] Bernick PE, Klimstra DS, Shia J et al (2004) Neuroendocrine carcinomas of the colon and rectum. *Dis Colon Rectum* 47:163–169. <https://doi.org/10.1007/s10350-003-0038-1>
- [2] Conte B, George B, Overman M et al (2016) High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. *Clin Colorectal Cancer* 15:e1-7. <https://doi.org/10.1016/j.clcc.2015.12.007>
- [3] Lee SM, Sung CO (2021) Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas. *Sci Rep* 11:6203. <https://doi.org/10.1038/s41598-021-85593-9>
- [4] Nam S, Kim D, Jung K et al (2020) Analysis of the Incidence and Clinical Features of Colorectal Nonadenocarcinoma in Korea: A National Cancer Registry-Based Study. *Ann Coloproctology* 36:390–397. <https://doi.org/10.3393/ac.2020.05.03.2>
- [5] Ottaiano A, Santorsola M, Perri F et al (2022) Clinical and Molecular Characteristics of Rare Malignant Tumors of Colon and Rectum. *Biology* 11:267. <https://doi.org/10.3390/biology11020267>
- [6] Patta A, Fakhri M (2011) First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. *Anticancer Res* 31:975–978
- [7] Pavel M, Öberg K, Falconi M et al (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 31:844–860. <https://doi.org/10.1016/j.annonc.2020.03.304>
- [8] Rindi G, Komminoth P, Scoazec JY, Shia J (2019) Colorectal neuroendocrine neoplasms. In: *Dig. Syst. Tumors*, 5th Aufl. WHO Press, Geneva, S 188–189
- [9] Rinke A, Collaborators: Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) et al (2018) S2k-Leitlinie Neuroendokrine Tumore: AWMF-Reg. 021-27. *Z Für Gastroenterol* 56:583–681. <https://doi.org/10.1055/a-0604-2924>
- [10] Shafiqat H, Ali S, Salhab M, Olszewski AJ (2015) Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. *Dis Colon Rectum* 58:294–303. <https://doi.org/10.1097/DCR.0000000000000298>
- [11] Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. *CA Cancer J Clin* 70:7–30. <https://doi.org/10.3322/caac.21590>
- [12] Smith JD, Reidy DL, Goodman KA et al (2014) A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. *Ann Surg Oncol* 21:2956–2962. <https://doi.org/10.1245/s10434-014-3725-3>
- [13] Sorbye H, Welin S, Langer SW et al (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. *Ann Oncol Off J Eur Soc Med Oncol* 24:152–160. <https://doi.org/10.1093/annonc/mds276>
- [14] Whitman J, Kardosh A, Diaz L et al (2019) Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair–Deficient Colorectal Neuroendocrine Carcinoma. *JCO Precis Oncol*:1–7. <https://doi.org/10.1200/PO.19.00098>
- [15] Yoshida T, Kamimura K, Hosaka K et al (2019) Colorectal neuroendocrine carcinoma: A case report and review of the literature. *World J Clin Cases* 7:1865–1875. <https://doi.org/10.12998/wjcc.v7.i14.1865>